The Warm Autoimmune Hemolytic Anemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Warm Autoimmune Hemolytic Anemia: An Overview
Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. According to NORD (National Organization of Rare Disorders), warm antibody hemolytic anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs.
Currently, there are no approved therapies for the management of WAIHA with only one-third of the patients maintaining sustained disease control once steroids are discontinued.
Warm Autoimmune Hemolytic Anemia (WAIHA) Market Key Facts
-
The total prevalent population of WAIHA in the 7MM was 82,045 in 2017. Estimates show that Secondary WAIHA comprises a higher number of cases as compared to Primary WAIHA cases.
-
According to DelveInsight’s analysis, females are affected more as compared to males in the case of warm autoimmune hemolytic anemia (WAIHA).
-
Among the 7MM, the estimates suggest a higher prevalence of WAIHA in the United States, with 32,138 cases in 2017.
-
Among the European 5 countries, Germany had the highest prevalent population of WAIHA, followed by France. On the other hand, Spain had the lowest prevalent population in 2017.
-
Warm autoimmune hemolytic anemia tends to affect adults more than children and adolescents in seven major markets.
Get FREE sample copy at: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
Key Benefits of Warm Autoimmune Hemolytic Anemia (WAIHA) Market Report
-
The report provides an in-depth analysis of Warm Autoimmune Hemolytic Anemia (WAIHA) Market Size and Share till 2030 in the seven major markets.
-
The report will help in developing business strategies by understanding the Warm Autoimmune Hemolytic Anemia Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
-
It covers Warm Autoimmune Hemolytic Anemia current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the WAIHA market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Warm Autoimmune Hemolytic Anemia (WAIHA) Market
The market size of warm autoimmune hemolytic anemia (WAIHA) is anticipated to increase during the study period, 2017–2030 in seven major markets. The increase in market size is a direct consequence of the rise in the prevalent population of WAIHA patients in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Warm Autoimmune Hemolytic Anemia market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the WAIHA market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology
The epidemiology section covers insights about the historical and current WAIHA patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Epidemiology Segmentation
-
Total Prevalent Cases of WAIHA
-
Diagnosed Prevalence of WAIHA
-
Type-specific Prevalence of WAIHA
-
Gender-specific Prevalence of WAIHA
Warm Autoimmune Hemolytic Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune Hemolytic Anemia (WAIHA) market or expected to get launched in the market during the study period. The analysis covers WAIHA market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the WAIHA Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
key companies involved in the development of novel drugs for Warm Autoimmune Hemolytic Anemia include:
-
Rigel Pharmaceuticals
-
Apellis Pharmaceuticals
-
Momenta Pharmaceuticals
-
Alexion
-
Immunovant
And many others.
Warm Autoimmune Hemolytic Anemia Therapies covered in the report includes:
-
Fostamitinib
-
APL-2
-
M281
-
IMVT-1401
-
ALXN1830
And many others.
Request for Sample @ Warm Autoimmune Hemolytic Anemia (WAIHA) Therapeutics Market Assessment
Table of Content
1. Key Insights
2. Executive Summary
3. Warm Autoimmune Hemolytic Anemia (WAIHA) Competitive Intelligence Analysis
4. Warm Autoimmune Hemolytic Anemia (WAIHA) Market Overview at a Glance
5. Warm Autoimmune Hemolytic Anemia (WAIHA) Disease Background and Overview
6. Warm Autoimmune Hemolytic Anemia (WAIHA) Patient Journey
7. Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology and Patient Population
8. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Algorithm, Current Treatment, and Medical Practices
9. Warm Autoimmune Hemolytic Anemia (WAIHA) Unmet Needs
10. Key Endpoints of Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment
11. Warm Autoimmune Hemolytic Anemia (WAIHA) Marketed Products
12. Warm Autoimmune Hemolytic Anemia (WAIHA) Emerging Therapies
13. Warm Autoimmune Hemolytic Anemia (WAIHA) Seven Major Market Analysis
14. Attribute Analysis
15. Warm Autoimmune Hemolytic Anemia (WAIHA) Market Outlook (7 major markets)
16. Warm Autoimmune Hemolytic Anemia (WAIHA) Access and Reimbursement Overview
17. KOL Views on the Warm Autoimmune Hemolytic Anemia (WAIHA) Market.
18. Warm Autoimmune Hemolytic Anemia (WAIHA) Market Drivers
19. Warm Autoimmune Hemolytic Anemia (WAIHA) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
Healthcare Blogs By DelveInsight
Nutraceutical Market Growth Analysis
The global demand for Nutraceuticals as a nutritional product for good health & well-being and as a medicine has grown significantly over the past two to three decades. As per DelveInsight, the Nutraceuticals Market is expected to grow at a CAGR of 8.82% by 2026, owing to the rising demand and proactive participation by global companies in the segment. The key companies dominating the global Nutraceutical Market include Koninklijke, Fonterra, DuPont, Nemours, Ingredion Incorporated, ADM, Tate & Lyle, Cargill, and several others. Read More: Nutraceutical Market
Onychomycosis Therapeutics Market Outlook
As per DelveInsight, the Onychomycosis market is expected to increase at a CAGR of 4.1% in the eight major countries (i.e the US, EU-5, Japan, and China) during the forecast period 2021-30, with the US occupying the majority of the therapy market share. Some of the prominent pharmaceutical and biotech companies such as Pfizer, Bausch Health Companies Inc., Sato Pharmaceutical Inc, Eisai US, Moberg Pharma AB, Blueberry Therapeutics Ltd, Mycovia Pharmaceuticals, Meiji Seika Kaisha, NovaBiotics, Hallux, and others are working in the Onychomycosis therapy market to meet the unmet needs. Read More: Onychomycosis Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/